Global Peripheral Arterial Disease (PAD) Therapeutics - Pharmaceuticals
NEW YORK, Feb. 20, 2017 /PRNewswire/ -- This report analyzes the worldwide markets for Peripheral Arterial Disease (PAD) Therapeutics in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World.
Read the full report: http://www.reportlinker.com/p04707127-summary/view-report.html
Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs.
The report profiles 23 companies including many key and niche players such as:
- AstraZeneca Plc
- Bayer HealthCare Pharmaceuticals
- Bristol-Myers Squibb Company
- Merck & Co., Inc.
- Proteon Therapeutics, Inc.
Read the full report: http://www.reportlinker.com/p04707127-summary/view-report.html
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1 Disclaimers.............. I-2 Data Interpretation & Reporting Level I-2 Quantitative Techniques & Analytics I-3 Product Definitions and Scope of Study I-3
II. EXECUTIVE SUMMARY
1. INDUSTRY OVERVIEW.............. II-1 PAD - A Prelude.............. II-1 PAD Statistics.............. II-2 Table 1: Prevalence of Peripheral Artery Disease by Age Group and Gender (includes corresponding Graph/Chart) II-3 Critical Limb Ischemia - An Insight II-3 High Costs - A Cause of Concern..............II-4
2. PAD THERAPEUTICS.............. II-5 Anti-Platelet Drugs: Spearheading the Battle against PAD II-5 Key Drugs for Arterial Disease II-6 Clopidogrel (Plavix)..............II-6 Prasugrel (Effient)..............II-7 Ticagrelor (Brilinta)..............II-7 Vorapaxar (Zontivity)..............II-8 Dual Antiplatelet Therapy (DAPT) for PAD II-8 Entry of Generics Tones Down Growth in Major Markets II-8 Brilinta Fails to Meet Expectations in EUCLID Trial II-9 Xarelto Pins Hope on COMPASS and VOYAGER trials II-10 Other Pipeline Drugs for Peripheral Arterial Disease (PAD) II-10 Cholesterol-Lowering Drugs: A Key Weapon in the Anti-PAD Arsenal II-11
3. MACRO GROWTH DRIVERS.............. II-12 Aging - A Key Driver..............II-12 Table 2: Global Aging Population (in Thousands) by Age Group: 1975-2050 (includes corresponding Graph/Chart) II-12
Table 3: Global Aging Population in Select Regions/Countries: Population of 60+ Individuals in '000s and as a Percentage of Total Population for 2015 & 2050 (includes corresponding Graph/Chart).............. II-13
Table 4: Life Expectancy at Age 60 and 80 Years - (2010-2015), (2020-2025) & (2045-2050) (includes corresponding Graph/Chart)..............II-14 High Diabetes Incidence Worldwide: Key Market Opportunity for PAD Therapeutics.............. II-14 Table 5: Worldwide Prevalence of Diabetes: Number of Adults (20-79) with Diabetes in 2015 and 2040 (includes corresponding Graph/Chart)..............II-15
Table 6: Global Prevalence of Diabetes - Number of Adults Diagnosed with Diabetes (in Million) by Gender for 2015 & 2040 (includes corresponding Graph/Chart) II-16
4. PERIPHERAL ARTERIAL DISEASE (PAD) - AN OVERVIEW II-17 Peripheral Arterial Disease: Understanding the Stealthy Peril II-17 Causes of PAD.............. II-17 Tobacco Use.............. II-17 Diabetes.............. II-17 Dyslipidemia.............. II-17 Hypertension.............. II-18 Causes of PAD in Lower Extremities II-18 Atherosclerosis.............. II-18 Blood Clotting.............. II-18 Link Established between Depression and PAD II-18 Ethyl-EPA Intake Proves Favorable for PAD Sufferers II-19 PAD Risk Factors.............. II-19 Symptoms of PAD.............. II-20 Claudication.............. II-20 Rest Pain.............. II-20 Other Symptoms.............. II-20 Prognosis of PAD.............. II-21 Diagnosis of PAD.............. II-21 Ankle Brachial Index (ABI)..............II-21 Ankle-Brachial Index and Associated Severity of Peripheral Arterial Disease.............. II-22 Magnetic Resonance Angiography (MRA) and CT Scan II-22 Control of PAD.............. II-22 Classification of PAD Severity II-23 Methods for Avoiding PAD Complications II-23 Treatment Options for Peripheral Arterial Disease - A General Perspective.............. II-23 Lifestyle Changes..............II-24 Surgery.............. II-24 Stenting.............. II-25 Artery Bypass Grafting..............II-25 Atherectomy.............. II-25 Breakthrough Atherectomy Device II-26 Amputation.............. II-26 Table 7: Leading PAD Treatment Approaches (2016): Percentage Share Breakdown of Number of Procedures for Atherectomy, Amputation, Bypass Surgery, and PTA/Stenting Procedures (includes corresponding Graph/Chart) II-26 Medication.............. II-27 Hopes Pinned on Stem Cell Therapy to Revolutionize PAD Treatment.............. II-27 Placenta-derived Stem Cell Therapy: A Promising Treatment for PAD.............. II-27
5. COMPANIES INTO GENE THERAPY FOR PAD II-29 AnGes MG, Inc. (Japan)..............II-29 Athersys, Inc. (US).............. II-29 Betagenon AB (Sweden)..............II-29 CardioVascular BioTherapeutics, Inc. (US) II-30 Celgene Corporation (US)..............II-30 ID Pharma Co., Ltd. (Japan)..............II-30 miRagen Therapeutics, Inc. (US)..............II-31 Multi Gene Vascular Systems Ltd (Israel) II-31 ViroMed Co. Ltd. (Korea)..............II-31
6. CLINICAL STUDIES/CORPORATE INITIATIVES II-32 AstraZeneca Announces Results of EUCLID Trial II-32 USPTO Extends Patent Term for Bayer's Rivaroxaban II-32 Bayer and Janssen Expand Clinical Development Programme for Rivaroxaban.............. II-32 FDA Approves Merck's Zontivity II-32
7. FOCUS ON SELECT GLOBAL PLAYERS..............II-33 AstraZeneca Plc. (UK)..............II-33 Bayer HealthCare Pharmaceuticals (Germany) II-33 Bristol-Myers Squibb Company (US) II-33 Merck & Co., Inc. (US)..............II-34 Proteon Therapeutics, Inc. (US)..............II-34 Sanofi S.A. (France)..............II-35 Symic Bio, Inc. (US)..............II-35 TheraVasc Inc. (US).............. II-35
8. GLOBAL MARKET PERSPECTIVE..............II-36 Table 8: World Recent Past, Current & Future Analysis for Peripheral Arterial Disease (PAD) Therapeutics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) II-36
Table 9: World Historic Review for Peripheral Arterial Disease (PAD) Therapeutics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).............. II-37
Table 10: World 14-Year Perspective for Peripheral Arterial Disease (PAD) Therapeutics by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) II-38
III. MARKET
1. THE UNITED STATES.............. III-1 A.Market Analysis.............. III-1 High PAD Incidence Drives Market III-1 Table 11: Prevalence of Peripheral Arterial Disease by Age Group, Ethnicity, and Gender (2015) III-2 Endovascular Intervention - A Review III-2 Table 12: Volume Percentage Change in Interventional Procedures Performed in the US (2006-2014) (includes corresponding Graph/Chart)..............III-3 Costs Associated with PAD Treatment III-3 Generics Steal Market Share from Plavix III-3 Aging Population Statistics & Diabetes Statistics: Key Opportunity Indicators..............III-4 Table 13: Aging Population in the US (2015 & 2030): 60 Years and Above Population (in Thousands) and Percentage of Population (includes corresponding Graph/Chart) III-4
Table 14: Diabetes and Population Statistics in North America and Caribbean Region (2015 & 2040) (includes corresponding Graph/Chart)..............III-5
Table 15: Diabetes Statistics in the US (2015) - Number of Adults with Diabetes (in 000s), Number of Adults with Undiagnosed Diabetes (in 000s), Diabetes Prevalence (%) and Number of Diabetes-Related Deaths (in '000s) III-5 Clinical Studies/Product Approvals/Corporate Developments III-5 Select Key Players..............III-6 B.Market Analytics..............III-9 Table 16: US Recent Past, Current & Future Analysis for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) III-9
Table 17: US Historic Review for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-10
2. CANADA.............. III-11 A.Market Analysis.............. III-11 Measures to Increase PAD Awareness III-11 B.Market Analytics..............III-12 Table 18: Canadian Recent Past, Current & Future Analysis for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) III-12
Table 19: Canadian Historic Review for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)..............III-13
3. JAPAN.............. III-14 A.Market Analysis.............. III-14 Table 20: Aging Population in Japan (2015 & 2030): 60 Years and Above Population (in Thousands) and Percentage of Population (includes corresponding Graph/Chart) III-14 Select Key Players..............III-14 B.Market Analytics..............III-16 Table 21: Japanese Recent Past, Current & Future Analysis for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) III-16
Table 22: Japanese Historic Review for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)..............III-17
4. EUROPE.............. III-18 A.Market Analysis.............. III-18 Plavix® Faces Generic and Branded Competition in Europe III-18 B.Market Analytics..............III-19 Table 23: European Recent Past, Current & Future Analysis for Peripheral Arterial Disease (PAD) Therapeutics by Geographic Region/Country - France, Germany, Italy, UK, Spain, and Rest of European Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) III-19
Table 24: European Historic Review for Peripheral Arterial Disease (PAD) Therapeutics by Geographic Region/Country - France, Germany, Italy, UK, Spain, and Rest of European Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)..............III-20
Table 25: European 14-Year Perspective for Peripheral Arterial Disease (PAD) Therapeutics by Geographic Region/Country - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, and Rest of European Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart).............. III-21
4a. FRANCE.............. III-22 A.Market Analysis.............. III-22 Sanofi - A Leading French Player III-22 B.Market Analytics..............III-23 Table 26: French Recent Past, Current & Future Analysis for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) III-23
Table 27: French Historic Review for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)..............III-24
4b. GERMANY.............. III-25 A.Market Analysis.............. III-25 Clinical Studies..............III-25 Select Players.............. III-25 B.Market Analytics..............III-26 Table 28: German Recent Past, Current & Future Analysis for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) III-26
Table 29: German Historic Review for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)..............III-27
4c. ITALY.............. III-28 Market Analysis.............. III-28 Table 30: Italian Recent Past, Current & Future Analysis for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) III-28
Table 31: Italian Historic Review for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)..............III-29
4d. THE UNITED KINGDOM..............III-30 A.Market Analysis.............. III-30 Clinical Studies..............III-30 AstraZeneca Plc: Key UK-Based Global Player III-30 B.Market Analytics..............III-31 Table 32: UK Recent Past, Current & Future Analysis for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) III-31
Table 33: UK Historic Review for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-32
4e. SPAIN.............. III-33 Market Analysis.............. III-33 Table 34: Spanish Recent Past, Current & Future Analysis for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) III-33
Table 35: Spanish Historic Review for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)..............III-34
4f. REST OF EUROPE.............. III-35 A.Market Analysis.............. III-35 Select Key Player.............. III-35 B.Market Analytics..............III-36 Table 36: Rest of European Recent Past, Current & Future Analysis for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) III-36
Table 37: Rest of European Historic Review for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) III-37
5. ASIA-PACIFIC.............. III-38 Market Analysis.............. III-38 Table 38: Asia-Pacific Recent Past, Current & Future Analysis for Peripheral Arterial Disease (PAD) Therapeutics by Geographic Region/Country - China and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) III-38
Table 39: Asia-Pacific Historic Review for Peripheral Arterial Disease (PAD) Therapeutics by Geographic Region/Country - China and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart).............. III-39
Table 40: Asia-Pacific 14-Year Perspective for Peripheral Arterial Disease (PAD) Therapeutics by Geographic Region/Country - Percentage Breakdown of Dollar Sales for China and Rest of Asia-Pacific Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart) III-40
5a. CHINA.............. III-41 Market Analysis.............. III-41 Table 41: Chinese Recent Past, Current & Future Analysis for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) III-41
Table 42: Chinese Historic Review for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)..............III-42
5b. REST OF ASIA-PACIFIC..............III-43 A.Market Analysis.............. III-43 India.............. III-43 Key Player.............. III-43 B.Market Analytics..............III-44 Table 43: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) III-44
Table 44: Rest of Asia-Pacific Historic Review for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) III-45
6. LATIN AMERICA.............. III-46 Market Analysis.............. III-46 Table 45: Latin American Recent Past, Current & Future Analysis for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) III-46
Table 46: Latin American Historic Review for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) III-47
7. REST OF WORLD.............. III-48 A.Market Analysis.............. III-48 Current and Future Analysis..............III-48 B.Market Analytics..............III-48 Table 47: Rest of World Recent Past, Current & Future Analysis for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart) III-48
Table 48: Rest of World Historic Review for Peripheral Arterial Disease (PAD) Therapeutics Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart) III-49
IV. COMPETITIVE LANDSCAPE
Total Companies Profiled: 23 (including Divisions/Subsidiaries - 25)
The United States (9) Canada (1) Japan (2) Europe (7) - France (1) - Germany (2) - The United Kingdom (1) - Rest of Europe (3) Asia-Pacific (Excluding Japan) (6)
Read the full report: http://www.reportlinker.com/p04707127-summary/view-report.html
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
http://www.reportlinker.com
__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001
SOURCE Reportlinker
Share this article